Treatment of juvenile idiopathic arthritis what's new?Giancane, Gabriellaa,b; Ruperto, Nicolinoa for the Paediatric Rheumatology International Trials Organisation (PRINTO)Current Opinion in Rheumatology: September 2019 - Volume 31 - Issue 5 - p 428–435 doi: 10.1097/BOR.0000000000000632 PEDIATRIC AND HERITABLE DISORDERS: Edited by Polly J. Ferguson Buy Abstract Author InformationAuthors Article MetricsMetrics Purpose of review The present review highlights the advances in disease outcome achieved with currently available biologic medications and future perspectives for JIA management. Recent findings In the last two decades, the management of juvenile idiopathic arthritis (JIA) has been revolutionized by appropriate legislative initiatives, the existence of very large collaborative networks and the increased availability of the novel biologic medications. Summary A more rational approach to the management of JIA is being fostered by the recent publication of therapeutic recommendations, consensus treatment plans and for a treat-to-target strategy. aIRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia – PRINTO bUniversità degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy Correspondence to Nicolino Ruperto, IRCCS G. Gaslini, Clinica Pediatrica e Reumatologia – PRINTO, Via Gaslini, 5, 16147 Genova, Italy. Tel: +39 1056362795; fax: +39 010 393324; e-mail: firstname.lastname@example.org Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.